Saltar al contenido
Merck

O-024

Supelco

Olanzapine solution

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización

Seleccione un Tamaño

1 ML
82,60 €

82,60 €


Póngase en contacto con nuestro Servicio de Atención al Cliente para disponibilidad

Solicitar un pedido a granel

Seleccione un Tamaño

Cambiar Vistas
1 ML
82,60 €

About This Item

Fórmula empírica (notación de Hill):
C17H20N4S
Número de CAS:
Peso molecular:
312.43
Número CE:
Código UNSPSC:
41116107
NACRES:
NA.24

82,60 €


Póngase en contacto con nuestro Servicio de Atención al Cliente para disponibilidad

Solicitar un pedido a granel

grado

certified reference material

Nivel de calidad

formulario

liquid

Características

Snap-N-Spike®/Snap-N-Shoot®

envase

ampule of 1 mL

fabricante / nombre comercial

Cerilliant®

concentración

1.0 mg/mL in acetonitrile

técnicas

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

aplicaciones

clinical testing

formato

single component solution

temp. de almacenamiento

−20°C

cadena SMILES

CN1CCN(CC1)C2=Nc3ccccc3Nc4sc(C)cc24

InChI

1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3

Clave InChI

KVWDHTXUZHCGIO-UHFFFAOYSA-N

Información sobre el gen

Descripción general

An analytical reference standard for use in LC/MS or GC/MS applications including clinical toxicology analysis or therapeutic drug monitoring. Marketed under the trade name Zyprexa®, olanzapine is an atypical antipsychotic drug used in the treatment of schizophrenia and bipolar disorder.

Aplicación

  • Metabolic impact of Olanzapine in bipolar disorder: A network meta-analysis of randomized-controlled trials assessed the metabolic effects of antipsychotics and mood stabilizers, including Olanzapine, in patients with bipolar disorder, providing insights into its pharmacodynamic properties and implications for treatment optimization (Kong et al., 2024).
  • Machine learning in schizophrenia research: Olanzapine′s effectiveness was evaluated through a systematic review employing machine learning to predict violent behaviors in schizophrenia spectrum disorders. This study underscores the relevance of antipsychotic treatment profiling in enhancing patient-specific therapeutic strategies (Delvecchio et al., 2024).
  • Solubility and bioavailability enhancement: Research focused on the evaluation of polymeric matrices for loading poorly water-soluble drugs, like Olanzapine, into mesoporous silica. This study advances the development of more effective and bioavailable oral liquid formulations of Olanzapine (Barmpalexis et al., 2024).

Información legal

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Zyprexa is a registered trademark of Eli Lilly and Co.

Pictogramas

FlameExclamation mark

Palabra de señalización

Danger

Clasificaciones de peligro

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

Código de clase de almacenamiento

3 - Flammable liquids

Clase de riesgo para el agua (WGK)

WGK 2

Punto de inflamabilidad (°F)

35.6 °F - closed cup

Punto de inflamabilidad (°C)

2 °C - closed cup


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Heating under high-frequency inductive conditions: application to the continuous synthesis of the neurolepticum olanzapine (Zyprexa).
Jan Hartwig et al.
Angewandte Chemie (International ed. in English), 52(37), 9813-9817 (2013-07-31)
Jean A Milstein et al.
PloS one, 8(2), e57308-e57308 (2013-02-26)
Antipsychotic drugs are increasingly used in children and adolescents to treat a variety of psychiatric disorders. However, little is known about the long-term effects of early life antipsychotic drug treatment. Most antipsychotic drugs are potent antagonists or partial agonists of
Joseph P McEvoy et al.
The Journal of clinical psychiatry, 74(2), 170-179 (2013-03-12)
To examine the effectiveness of switching patients to lurasidone using 3 different dosing strategies. Adults with DSM-IV-defined schizophrenia or schizoaffective disorder in a nonacute phase of illness were randomized to 1 of 3 lurasidone dosing regimens for the initial 2
A case of atypical antipsychotic-induced somnambulism: a class effect.
Yael Dagan et al.
The Journal of clinical psychiatry, 74(4), 370-370 (2013-05-10)
Stephen M Stahl et al.
The Journal of clinical psychiatry, 74(5), 507-515 (2013-04-02)
The primary objective was to evaluate the safety and tolerability of lurasidone, a new atypical antipsychotic agent, in the longer-term treatment of schizophrenia (DSM-IV). Persistence of symptom improvement was assessed as a secondary outcome. Patients who completed a 6-week, double-blind

Preguntas

Revisiones

Sin puntuación

Filtros activos

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico